Cerecor CEO to Present at the H.C. Wainwright Global Investment Conference
August 31, 2018 07:00 ET
|
Cerecor, Inc.
BALTIMORE, Aug. 31, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on the near-term goal of becoming a leader in the U.S. pediatric market space, today...
Cerecor Reports Second Quarter 2018 Financial Results
August 09, 2018 06:30 ET
|
Cerecor, Inc.
BALTIMORE, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), an integrated biopharmaceutical company focused on pediatric healthcare and developing innovative therapies that make a...
Cerecor Announces First Patient Enrolled in Phase I Trial for Neurogenic Orthostatic Hypotension (nOH) in Parkinson’s Disease
August 01, 2018 06:30 ET
|
Cerecor, Inc.
Study to evaluate safety, tolerability and effects on blood pressure of CERC-301 in patients with nOH BALTIMORE, Md., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), today announced...
Cerecor Announces Expansion of Leadership Team
July 16, 2018 06:00 ET
|
Cerecor, Inc.
New Leadership Supports Company Evolution into Innovative Specialty Pharmaceutical Company BALTIMORE, July 16, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), today announced executive...
Cerecor Reports First Quarter 2018 Financial Results
May 11, 2018 08:15 ET
|
Cerecor, Inc.
BALTIMORE, May 11, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC) (“Cerecor” or the “Company”) today announced financial results for the first quarter of 2018. Net revenues for the first...